首页> 外文期刊>Ethiopian journal of health sciences >The Effect of Oral Simvastatin on the Clinical Outcome of Patients with Severe Traumatic Brain Injury: A Randomized Clinical Trial
【24h】

The Effect of Oral Simvastatin on the Clinical Outcome of Patients with Severe Traumatic Brain Injury: A Randomized Clinical Trial

机译:口服辛伐他汀对严重创伤性脑损伤患者临床结果的影响:随机临床试验

获取原文
           

摘要

Despite recent promising pharmacological and technological advances in neurosurgical intensive care, the overall TBI-related mortality and morbidity remain high and still pose a major clinical problem. The aim of this study was to evaluate the effect of oral simvastatin on the clinical outcome of patients with severe TBI. METHODS: In a double-blind placebo-controlled randomized clinical trial a total of 98 patients with severe TBI in Imam Khomeini Hospital in Sari, Iran, were evaluated. Patients who meet the inclusion criteria were randomly allocated into two groups (n=49). In addition to supportive therapies, the intervention group received oral simvastatin (40 mg, daily) for 10 days, and the control group received the placebo (10 days). Patients' Glasgow coma scale (GCS) score, in hospital mortality, duration of mechanical ventilation and length of ICU and neurosurgery ward stay were evaluated during three-time intervals (T1: admission, T2: discharge and T3: one month after discharge). RESULTS: The percentage of conscious patients was 18.9% (7 cases) in the simvastatin group and 3.1% (1 case) in controls (P=0.06) at T2. One month after discharge (T3) the proportion of conscious patients significantly increased in the simvastatin group compared to control group (64.9 % versus 28.1 %; P=0.002). There was no significant difference for the mean of GCS score between the simvastatin group and control group at T1 (6.41 ± 1.30 versus 6.41 ± 1.28, respectively; P = 0.98). However, the mean score of GCS in patients who received simvastatin was significantly greater than controls at T2 and T3 (p<0.05). There was no significant differences between two group in-terms of length of mechanical ventilation, ICU and neurosurgery ward stay. CONCLUSION: According to the results of this study it seems that using simvastatin may be an effective and promising therapeutic modality for improving GCS score during TBI recovery.
机译:尽管最近有前途的神经外科重症监护人员的药理学和技术进步,但总体TBI相关的死亡率和发病率仍然很高,仍然是一个重大的临床问题。本研究的目的是评估口服辛伐他汀对严重TBI患者临床结果的影响。方法:在伊朗莎丽伊曼伊曼伊曼奥姆霍梅尼医院共有98例严重TBI患有98例患者的双盲安慰剂随机临床试验。符合纳入标准的患者被随机分配为两组(n = 49)。除了支持性疗法之外,干预组除了10天的口服辛伐他汀(每日40毫克,每日40毫克),对照组接受安慰剂(10天)。患者的Glasgow Coma Scale(GCS)得分,在医院死亡率,ICU机械通气持续时间和ICU和神经外科病房的长度进行评估(T1:入场,T2:排放和T3:出院后一个月)。结果:在辛伐他汀组中,有意识患者的百分比为18.9%(7例),T2的对照组(P = 0.06)。放电后一个月(T3)与对照组相比,辛伐他汀组中有意识患者的比例显着增加(64.9%对28.1%; P = 0.002)。在T1的辛伐他汀组和对照组之间的GCS评分的平均值没有显着差异(分别为6.41±1.30与6.41±1.28; P = 0.98)。然而,接受辛伐他汀的患者的GCS的平均得分明显大于T2和T3的对照(P <0.05)。两组在机械通气,ICU和神经外科病房留下没有显着差异。结论:根据本研究的结果,似乎使用辛伐他汀可能是一种有效和有前途的治疗方式,用于在TBI恢复过程中改善GCS得分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号